Ceregene
The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease
Published in Gene Therapy Weekly, July 8th, 2010
The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD) progression. The competitive funding was awarded as part of the MJFF 2010 LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) program on neurotrophic factors.
"Ceregene is enthusiastic about the continued support...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-07-08)
More Articles from Gene Therapy Weekly
- Gene Therapy
Arrowhead Announces Closing of $8.65 Million Registered Direct Offering - Microbiology and Biotechnology
Chongqing University, Engineering Research Center reports research in microbiology and biotechnology - The Michael J. Fox Foundation for Parkinson's Research
Michael J. Fox Foundation Awards $4.6 Million to Help Advance Neurotrophic Factors as Transformative Parkinson's Treatments - Agriculture and Seed Science
New findings reported from Oregon State University describe advances in agriculture and seed science - Gene Therapy
New gene therapy findings from Chinese Academy of Science published - Gene Therapy
New gene therapy study findings have been reported by P. Andreozzi and colleagues - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
